Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Inflation, housing market: Same as it ever was

Wed, 13th Jan 2021 16:06

* Major US indexes gyrate, now mixed: Nasdaq, S&P gain, Dow
slips

* Utilities lead S&P sector gainers; materials weakest group

* Euro STOXX 600 edges higher

* Dollar, gold rise; crude dips

* US 10-Year Treasury yield ~1.11%

Jan 13 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

INFLATION, HOUSING MARKET: SAME AS IT EVER WAS (1105
EST/1605 GMT)

U.S. data released on Wednesday shocked exactly no one with
the alarming news that inflation is cool and the housing market
is hot - same song, thousandth verse.

The prices American consumers pay for a basket of items -
the consumer price index (CPI) - increased by 0.4%
in December according to the Labor Department, inline with
consensus and an acceleration from November's 0.2% growth.

The gain was primarily driven by an 8.4% jump in gasoline
prices. Stripping away volatile food and energy prices,
so-called "core CPI" grew by a paltry 0.1%.

Year over year, core CPI growth held firm at 1.6%, well
below the U.S. Federal Reserve's average annual inflation target
of 2%. While the Fed's preferred inflation yardstick is the PCE
index, the languid inflation numbers from nearly every major
indicator suggests the central bank's easy monetary policy isn't
going anywhere for the time being.

"Sluggish aggregate demand keeps underlying price pressures
at bay," writes Kathy Mostjancic, chief U.S. financial economist
at Oxford Economics (OE). "Moreover, the ongoing pandemic
continues to depress gains in core service prices."

It's always a good idea to revisit our old friend The Misery
Index. While the MI takes different forms, it's generally
considered to be the sum of the unemployment rate and annual
inflation growth.

As seen in the graphic below, the MI increased in 2020's
final month for the first time since April:

Finally, demand for home loans jumped by an impressive 16.7%
last week, according to the Mortgage Bankers Association (MBA).

Even with the average 30-year fixed contract rate
inching up 2 basis points to a still-historically-low 2.88%,
refi applications, which accounted for 74.8% of the
total, surged by more than 20%. Demand for loans to purchase
homes rose by 8%.

"Sustained housing demand continued to support purchase
growth, with activity up nearly 10 percent from a year ago,"
said Joel Kan, Associate Vice President of Economic and Industry
Forecasting at MBA.

But can the housing market, the darling of the U.S. economic
recovery, continue its impressive run? Perhaps not.

"We expect some moderation in the pace of home sales from
the late 2020 pace, as rising home prices and limited
inventories constrain sales," says Nancy Vanden Houten, lead
economist at OE.

Investors had difficulty deciding on whether to accentuate
the positive or the negative in morning trading, with the major
U.S. indexes ping-ponging between red and green.

Chips seem determined to have a good day, while
economically sensitive small caps and transports
are easing off Tuesday's record closing highs.

(Stephen Culp)

*****

EUROPEAN STOCKS: UNLOVED FOR THE PAST TWO DECADES, WHAT
ABOUT THE NEXT? (1045 EST/1545 GMT)

While Wall Street and Asian stocks are at all-time highs,
Europe is clearly lagging and has been for the past 20 years.

The old continent's share in the value of global equities
has almost halved over the past two decades, to 17% from over
30%, as per BofA Global Research.

The U.S. bank blames it on the absence of FAANGs, bigger
exposure to cheap sectors like banks and energy, aging
population, pressures from de-globalisation and climate change,
slower GDP growth versus rest of the developed world.

Apparently, Apple sells more watches than the
entire Swiss watch industry, and Cisco's market cap is
more than that of leading telecom service providers in UK,
France, Spain, Italy and Switzerland, combined, according to the
note.

What does the future look like for European investors? BofA
lists a handful of sectors that could shape the markets in the
next decade.

FANGMAN to GRANS: While U.S. remains a FANGMAN
market(Facebook, Amazon, Alphabet,
Microsoft, Apple, Netflix), Europe is
dominated by GRANS (GlaxoSmithKline, Roche,
AstraZeneca, Novartis, Sanofi).
Healthcare has been among the sectors whose markets weightings
have grown in the wake of the pandemic.

CLIMATE ACTION: Eight of the top 10 clean energy companies
by market cap are in Europe, which is also the undisputed leader
of ESG markets.

LUXURY: Luxury companies in Europe are worth more than its
autos sector, while in 2009 they were worth less than one-third;
LVMH is valued more than 4x Daimler, the largest
European carmaker.

GOLDEN AGE FOR EU CLEANTECH: 85% of Europe's electricity is
expected to be from zero-carbon sources by 2030 vs. 57% in 2020;
BofA sees tailwind from economics, policy, funding, tech
innovation and consumer adoption.

Even so, BofA says Europe's pro-cyclical nature and a weak
domestic growth means that European EPS only outperforms during
periods of strong global growth, and it's lack of exposure to
high-growth sectors like technology will drive its structural
underperformance in future.

(Sruthi Shankar)

*****

U.S. STOCKS WAFFLE, THEN HEAD SOUTH (1008 EST/1508 GMT)

Wall Street waffled on Wednesday after the opening bell,
strobing between green then red - but seemed to decide, a
half-hour into the session, to settle in negative territory.

There was little in the way of a catalyst to turn investor
moods sour or sweet. The ongoing vaccine rollout and
expectations for more generous fiscal stimulus from the incoming
Biden administration was again offset by the resurgent pandemic
and the unfolding drama in Washington.

The U.S. House of Representatives is expected to vote for
the second time within 12 months to impeach President Donald
Trump, this time for inciting an insurrection.

That insurrection caught the attention of U.S. Federal
Reserve officials, who said on Tuesday that while concerns about
continued violence pose a risk, but the transition to a new
administration on Jan. 20, and a likely accelerating vaccine
rollout have left them optimistic.

On the economic front, CPI data appeared to confirm tepid
inflation that can keep the Fed's monetary policy accommodative
for the foreseeable future.

In a reversal from Tuesday, economically sensitive small
caps and transports are underperforming the
broader market.

Here's your opening snapshot:
(Stephen Culp)

*****

TECH VS FINANCIALS: COMING BACK TO EARTH (0900 EST/1400 GMT)

After an unprecedented streak of consecutive higher monthly
closes that ended in August of last year, the S&P 500 tech
sector / S&P 500 financial sector ratio has
been coming back to earth.

This, as value took the reins from growth.

Indeed, the tech / financials ratio ended at 5.23 in August,
after having logged 11-straight higher monthly closes. (Click on
chart below)

That's one more month than the 10-month win streak the ratio
recorded into the Nasdaq/tech sector October 2007 top.
It was also this ratio's longest streak of higher monthly closes
using Refinitiv data back to 1989.

Additionally, through August, the ratio ended above its
upper monthly Bollinger Band (BB) for eight straight months
(more than two standard deviations above its 20-month moving
average). That was also its longest such streak going back to
1989. Thus, the ratio appeared especially high on a relative
basis.

With September's downtick, the ratio came back inside the
upper monthly BB, suggesting potential for a more significant
reversal.

Now, at 4.36, the ratio is on track to fall for a 5th
straight month. A continued decline to even just meet the rising
20-month moving average, now around 3.99, would suggest
additional tech underperformance relative to financials, and
with this, likely further growth underperformance vs value.

(Terence Gabriel)

*****

FOR WEDNESDAY'S LIVE MARKETS' POSTS PRIOR TO 0900 EST/1400
GMT - CLICK HERE:

(Terence Gabriel is a Reuters market analyst. The views
expressed are his own)

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.